2-(嘧啶-2-基)丙二酸二乙酯 | 164296-40-6

• 物质功能分类: 医药中间体 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2-(嘧啶-2-基)丙二酸二乙酯
• 英文名称: diethyl 2-(pyrimidin-2-yl)malonate
• 英文别名: diethyl (2-pyrimidinyl) malonate；diethyl (2-pyrimidinyl)malonate；diethyl 2-pyrimidin-2-ylpropanedioate
• CAS: 164296-40-6
• 化学式: C₁₁H₁₄N₂O₄
• mdl: MFCD00720665
• 分子量: 238.243
• InChiKey: GDSDUMCXSKBVSG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  78.4
• 氢给体数：
  0
• 氢受体数：
  6

安全信息

• 海关编码：
  2933599090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-(2-Pyrimidinyl)propanedioic acid 1,3-diethyl ester
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-(2-Pyrimidinyl)propanedioic acid 1,3-diethyl ester
CAS number: 164296-40-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H14N2O4
Molecular weight: 238.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-(嘧啶-2-基)丙二酸二乙酯 在 水 、 sodium ethanolate 、 sodium chloride 、 三氯氧磷 作用下， 以 乙醇 、 二甲基亚砜 为溶剂， 反应 8.75h， 生成 3-chloro-5-(4-chlorophenyl)-6-methyl-4-(2-pyrimidinyl)pyridazine
  参考文献：
  名称：

  PYRIDAZINE COMPOUND AND USE THEREOF

  摘要：

  公开号：

  EP1958946B1
• 作为产物：
  描述：

  2-氯嘧啶 、 丙二酸二乙酯 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 2-(嘧啶-2-基)丙二酸二乙酯
  参考文献：
  名称：

  PYRIDAZINE COMPOUND AND USE THEREOF

  摘要：

  公开号：

  EP1958946B1

文献信息

• Pyridine Non-Classical Cannabinoid Compounds and Related Methods of Use
  申请人：Moore, II Bob M.

  公开号：US20090286818A1

  公开（公告）日：2009-11-19

  wherein R 1 , R 2 , V, W, X, Y and Z can be as defined herein. The compounds can be used in the treatment of disorders mediated by the cannabinoid receptors.

  其中R1、R2、V、W、X、Y和Z可以如本文所定义。这些化合物可用于治疗由大麻素受体介导的疾病。
• Piperidine and tetrahydropyridine derivatives
  申请人：Merck Sharp & Dome Ltd.

  公开号：US05973156A1

  公开（公告）日：1999-10-26

  A class of substituted piperidine and tetrahydropyridine derivatives, linked through the 4-position thereof via an alkylene chain to a fused bicyclic heteroaromatic moiety such as indolyl, and further substituted at the 1-position by an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl-alkyl, aryl-alkyl or heteroaryl-alkyl moiety, are selective agonists of 5-HT.sub.1 -like receptors, being potent agonists of the human 5-HT.sub.1D.spsb..alpha. receptor subtype whilst processing at least a 10-fold selective affinity for the 5-HT.sub.1D.spsb..alpha. receptor subtype relative to the 5-HT.sub.1D.spsb..beta. subtype; they are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT.sub.1D receptors is indicated, whilst eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT.sub.1D receptor agonists.

  一类经过取代的哌啶和四氢吡啶衍生物，通过其4位点通过一条烷基链连接到融合的双环杂芳基团，如吲哚，并且在1位点进一步经过取代为一个可选择取代的烷基，烯基，炔基，环烷基-烷基，芳基-烷基或杂芳基-烷基团，是5-HT.sub.1-类受体的选择性激动剂，是人类5-HT.sub.1D.spsb..alpha.受体亚型的有效激动剂，同时相对于5-HT.sub.1D.spsb..beta.亚型至少具有10倍的选择性亲和力；因此，在治疗和/或预防临床疾病，特别是偏头痛和相关疾病方面，这些衍生物是有用的，因为这些疾病需要5-HT.sub.1D受体的亚型选择性激动剂，同时引起的副作用较少，尤其是不良心血管事件，比与非亚型选择性5-HT.sub.1D受体激动剂相关的副作用。
• Synthesis and RNA-Binding Properties of Extended Nucleobases for Triplex-Forming Peptide Nucleic Acids
  作者：Ilze Kumpina、Nikita Brodyagin、James A. MacKay、Scott D. Kennedy、Martins Katkevics、Eriks Rozners

  DOI：10.1021/acs.joc.9b01133

  日期：2019.11.1

  Triple-helix formation, using Hoogsteen hydrogen bonding of triplex-forming oligonucleotides, represents an attractive method for sequence-specific recognition of double-stranded nucleic acids. However, practical applications using triple-helix-forming oligonucleotides and their analogues are limited to long homopurine sequences. The key problem for recognition of pyrimidines is that they present only

  使用三链形成寡核苷酸的Hoogsteen氢键形成三螺旋，代表了一种有吸引力的方法，用于对双链核酸进行序列特异性识别。然而，使用形成三螺旋的寡核苷酸及其类似物的实际应用限于长的高嘌呤序列。识别嘧啶的关键问题是，它们在大沟中仅存在一个氢键受体或供体基团。本文中，我们报告了我们的首次尝试，通过使用经扩展核碱基修饰的肽核酸（PNA）来解决此问题，该核碱基沿Watson-Crick碱基对的整个Hoogsteen边缘形成三个氢键。设计了新的核碱基三元组（五个），并通过从头算来证实了它们的氢键可行性。合成携带修饰的核碱基的PNA单体，并将其掺入短模型PNA序列中。等温滴定量热法显示这些核碱基对其双链RNA（dsRNA）靶标具有适度的结合亲和力。最后，在PNA-dsRNA螺旋中修饰的三元组的分子模型表明适度的结合亲和力是由与理想氢键排列的细微结构偏差或延伸的核碱基支架的π堆积破坏引起的。
• [EN] COMPOUNDS AND THEIR METHODS OF USE<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：AGIOS PHARMACEUTICALS INC

  公开号：WO2014079150A1

  公开（公告）日：2014-05-30

  Provided are compounds of formula (I), which can inhibit glutaminase. Pharmaceutical compositions comprising these compounds and uses as glutaminase inhibitors for treating cancers thereof are also provided.

  提供了化合物的化学式(I)，可以抑制谷氨酸酶。还提供了包含这些化合物的药物组合物，并用作抑制谷氨酸酶以治疗相关癌症的用途。
• Pyrimidine Non-Classical Cannabinoid Compounds and Related Methods of Use
  申请人：Moore, II Bob M.

  公开号：US20090286810A1

  公开（公告）日：2009-11-19

  Disclosed are compounds of the formula I: wherein R 1 , R 2 , V, W, X, Y and Z can be as defined herein. The compounds can be used in the treatment of disorders mediated by the cannabinoid receptors.

  揭示了公式I的化合物：其中R1、R2、V、W、X、Y和Z可以如本文所定义。这些化合物可用于治疗由大麻素受体介导的疾病。